For research use only. Not for therapeutic Use.
Strontium Ranelate(Cat No.:A000439)is a medication used to treat osteoporosis, particularly in postmenopausal women and individuals at high risk of fractures. It has a dual mechanism of action: promoting bone formation by stimulating osteoblast activity and reducing bone resorption by inhibiting osteoclasts. This unique profile helps improve bone density and reduce the risk of vertebral and hip fractures. Strontium Ranelate is often prescribed when other treatments are unsuitable. However, it requires careful monitoring due to potential side effects, such as cardiovascular risks, making it a second-line option in osteoporosis management.
Catalog Number | A000439 |
CAS Number | 135459-87-9 |
Synonyms | 135459-87-9; Protelos; Protos; Distrontium renelate; Osseor |
Molecular Formula | C12H6N2O8SSr2 |
Purity | ≥95% |
Target | CaSR |
Solubility | Limited solubility |
Storage | -20°C |
IUPAC Name | distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate |
InChI | InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4 |
InChIKey | XXUZFRDUEGQHOV-UHFFFAOYSA-J |
SMILES | C(C1=C(SC(=C1C#N)N(CC(=O)[O-])CC(=O)[O-])C(=O)[O-])C(=O)[O-].[Sr+2].[Sr+2] |
Reference | 1: Lavet C, Mabilleau G, Chappard D, Rizzoli R, Ammann P. Strontium ranelate 2: Masalskas BF, Martins Júnior W, Leoni GB, Faloni APS, Marcaccini AM, Silva 3: Strontium ranelate discontinued. Drug Ther Bull. 2017 Aug;55(8):93-94. doi: 4: Rodrigues TA, Sampaio AJB Junior, Nunes IDP, Cartágenes MSS, Garcia JBS. <br> 6: Pan WL, Chen PL, Lin CY, Pan YC, Ju YR, Chan CP, Hsu RW. Strontium ranelate <br> 8: Moreno-Higueras M, Callejas-Rubio JL, Gallo-Padilla L. Dress syndrome and 9: Alves SM, Abreu SC, Lemos JC, Gomes FIF, Alves SM, do Val DR, Freitas RS, 10: Pilmane M, Salma-Ancane K, Loca D, Locs J, Berzina-Cimdina L. Strontium and |